Jump to main content
Jump to site search

Issue 3, 2015
Previous Article Next Article

Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth

Author affiliations

Abstract

Axitinib (AXT) is a potent and selective orally administered inhibitor of the vascular endothelial growth factor receptors 1–3 that contribute to the pathogenesis of solid tumors. The goal of the present study was to enhance the antiangiogenic and antitumor effects of AXT under hypoxia. Here we developed spherical polypeptide-coated hybrid liposomal nanoparticles (P-LNP/AXT) with a narrow size distribution and high loading efficiency. The cytotoxic effects of P-LNP/AXT on cancer cells were lower than those of AXT, and the human cancer cell lines SCC7, BT-474, and SH-SY5YP efficiently incorporated P-LNP/AXT. However, these formulations were not significantly internalized by the mouse macrophage cell line RAW 264.7, suggesting that they could evade the reticuloendothelial system. Western blotting analysis showed a significant increase in the level of expression of hydroxy-HIF-1α when cells were treated with P-LNP/AXT. The growth of tumors in mice treated with P-LNP/AXT was significantly inhibited compared with controls. Further, elevated levels of caspase-3 and poly (ADP-ribose) polymerase and reduced levels of platelet/endothelial cell adhesion molecule 1 (PECAM1, CD31) and Ki-67 in tumor cells suggested that tumor cells underwent apoptosis and that angiogenesis was inhibited within the tumor. Thus, P-LNP/AXT shows promise for cancer chemotherapy by inhibiting tumor angiogenesis.

Graphical abstract: Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth

Back to tab navigation

Publication details

The article was received on 31 Aug 2014, accepted on 28 Oct 2014 and first published on 29 Oct 2014


Article type: Paper
DOI: 10.1039/C4TB01442A
Citation: J. Mater. Chem. B, 2015,3, 408-416
  •   Request permissions

    Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth

    J. Y. Choi, T. Ramasamy, T. H. Tran, S. K. Ku, B. S. Shin, H. Choi, C. S. Yong and J. O. Kim, J. Mater. Chem. B, 2015, 3, 408
    DOI: 10.1039/C4TB01442A

Search articles by author

Spotlight

Advertisements